Pushing Back on Kickbacks: $900 Million Settlement in Biotech False Claims Act Case
On the eve of a trial with a former employee turned whistleblower, biotechnology company Biogen agreed to pay $900 million to settle allegations of lavishly overpaying doctors to prescribe their drugs to Multiple Sclerosis (MS) patients.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.